Scalper1 News
Medical giant Johnson & Johnson (JNJ) beat Wall Street’s Q2 estimates and lifted its guidance Tuesday, but the stock was off a fraction in early trading as revenue declined. Earnings excluding special items shrank 4% from the year-earlier quarter to $1.71 a share, beating analysts’ consensus by 4 cents, according to Thomson Reuters. Excluding the impact of foreign exchange rates, profit rose 6.7%. Revenue fell 8.8% to $17.8 billion, in line with Scalper1 News
Scalper1 News